Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.15 USD
-0.13 (-1.79%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $7.16 +0.01 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TERN 7.15 -0.13(-1.79%)
Will TERN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TERN
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice
Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE
Other News for TERN
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Ventyx Biosciences (VTYX) and Walgreens Boots Alliance (WBA)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Buy Rating Upheld for Terns Pharmaceuticals Amid Strong Prospects for TERN-701 and Financial Stability
Tern Plc Updates Share Capital and Voting Rights
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences